Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 5,926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Chronic Hepatitis B
Interventions: TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more

Conditions: Head and Neck Cancer
Interventions: proteomic profiles; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Acute Coronary Syndrome
Interventions: Milvexian, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 162
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Camizestrant, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more

Conditions: Alveolar Bone Loss, Periodontal Diseases
Interventions: beta-tricalcium phosphate alone, GFeBGS 0.1%, GFeBGS 0.3%, GFeBGS 0.4%; Device
Lead sponsor: Sunstar Americas; Industry
Eligibility: 25 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Fullerton, California • Aurora, Colorado + 3 more

Conditions: Pompe Disease (Late-onset)
Interventions: AT2221, ATB200; Drug · Biological
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more

Conditions: Hypercholesterolemia, Familial, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Food Allergy
Interventions: ADP101; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 57 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions: TTI-101; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Myelofibrosis (MF)
Interventions: Placebo for Navitoclax, Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 35
States / cities: Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 12
States / cities: Flemington, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 9 more

Conditions: Critical Illness
Interventions: Oral Care; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia + 1 more

Conditions: Breast Neoplasms
Interventions: neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo (for azithromycin), inhaled tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 39
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 33 more

Conditions: STD
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 26 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Crohn Disease
Interventions: Lactulose/Rhamnose solution, MB-102; Drug
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Asthma, Allergic Sensitization
Interventions: Oral mucosal immunoprophylaxis (OMIP), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Months to 30 Months
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Dental Caries
Interventions: Negative Control Toothpaste, Active Comparator, Test toothpaste; Drug
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Noblesville, Indiana

Conditions: Non Small Cell Lung Cancer
Interventions: PF-02341066, PF-00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: Aurora, Colorado • Bethesda, Maryland • Boston, Massachusetts

Conditions: Prematurity
Interventions: Oral feeding; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 7 Weeks
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peanut Allergy
Interventions: AR101; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 47
States / cities: Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more

Conditions: Stomatitis, Oral Mucositis, Neoplasm of the Breast, Malignant Tumor of Breast
Interventions: Miracle Mouthwash Plus Hydrocortisone, Prednisolone; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: US, Texas

Conditions: Undesired Intrauterine Pregnancy, First Trimester Pregnancy
Interventions: Intravenous moderate sedation versus oral medication; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years to 55 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

Open-label Extension Study of ADP101

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

Study Evaluating HKI-272 in Tumors

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

Study of Oral Papillomavirus In Teens and Twenties

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

Intra Oral Appliance (IOA) Model Evaluating the Efficacy of Sensitive Toothpaste

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Initiation of Oral Feeding at 30 Versus 33 Weeks Postmenstrual Age

PALISADE Follow-on Study (ARC004)

Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus

Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions